Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.
about
Pharmacogenomics of off-target adverse drug reactions.ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approachesDiagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Clinical Trial Design in Juvenile Idiopathic Arthritis.Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC).Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Integrating pharmacogenomics into electronic health records with clinical decision support.Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.Concepts of Genomics in Kidney Transplantation.Comparison of genome sequencing and clinical genotyping for pharmacogenes.Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.Diagnosing and managing patients with drug hypersensitivity.Biomarkers of adverse drug reactions.Clinical Pharmacology & Therapeutics: Past, Present, and Future.Comparison between the HLA-B∗58 : 01 Allele and Single-Nucleotide Polymorphisms in Chromosome 6 for Prediction of Allopurinol-Induced Severe Cutaneous Adverse Reactions.Patient ethnicity and the risk of immune-mediated adverse drug reactions.Genetic Testing in Clinical Settings.ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with goutPharmacogenetic Markers of Drug Hypersensitivity in a Thai Population
P2860
Q30400366-4A482BF7-8E3D-4F6A-8CF0-F98CEE929E5BQ33602553-7617C7F1-56CD-4098-BD28-687B8C2FB09EQ38600529-7087036A-ED10-4901-B32F-8D5DE30D243FQ38671265-0D6932F0-8EFE-4D85-B254-6DF88D089F0AQ38888585-70546362-CFFA-4628-8C7E-A3FBCE124086Q39173298-60932A8A-1B66-41A1-9A45-411135BB3650Q39173300-F8D194FF-3F61-4279-8E2C-1CBC15755465Q39291741-E776E66C-612D-4636-9538-999353EBF7F7Q46684824-4BED7D08-C73E-4502-863D-10A364EC2AB4Q47128107-8CB261A4-A851-456E-A79B-6E80CD616F68Q47546923-CB7B3E34-D472-403D-B0FA-CD96C93F8BB8Q47569828-ADE633D1-DFDB-426C-B488-E48CD1356824Q47928481-31433B20-971A-4C0C-A7CB-2DD535CB666AQ48059492-B7236C3B-3CF4-4081-9014-C427E2ECB6DEQ48119431-23722F9C-7141-485A-BAAF-B476F3242420Q49617664-AD63490E-9671-46BF-BC75-0C40D17B0C38Q52588359-CCCF1475-7139-48D3-AFC3-3F1984553C8FQ57154626-FAE878F5-EA2D-4E56-986E-A8BC221C37CFQ58799157-5C808E1D-99B7-4813-8AD2-E6C0E7A5E0D7
P2860
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical Pharmacogenetics Impl ...... lopurinol dosing: 2015 update.
@ast
Clinical Pharmacogenetics Impl ...... lopurinol dosing: 2015 update.
@en
type
label
Clinical Pharmacogenetics Impl ...... lopurinol dosing: 2015 update.
@ast
Clinical Pharmacogenetics Impl ...... lopurinol dosing: 2015 update.
@en
prefLabel
Clinical Pharmacogenetics Impl ...... lopurinol dosing: 2015 update.
@ast
Clinical Pharmacogenetics Impl ...... lopurinol dosing: 2015 update.
@en
P2093
P2860
P356
P1476
Clinical Pharmacogenetics Impl ...... llopurinol dosing: 2015 update
@en
P2093
B R Goldspiel
Clinical Pharmacogenetics Implementation Consortium
E J Phillips
J T Callaghan
K E Caudle
M S Hershfield
N Kamatani
P2860
P356
10.1002/CPT.161
P407
P577
2015-07-16T00:00:00Z